Literature DB >> 21556024

Targeted therapies: peaking beneath the surface of recent bevacizumab trials.

Ana M Gonzalez-Angulo, Gabriel N Hortobagyi, Lee M Ellis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21556024     DOI： 10.1038/nrclinonc.2011.66

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.

Authors:  David Miles; Nadia Harbeck; Bernard Escudier; Herbert Hurwitz; Leonard Saltz; Eric Van Cutsem; Jim Cassidy; Barbara Mueller; Florin Sirzén
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

Review 2.  Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.

Authors:  Vishal Ranpura; Sanjaykumar Hapani; Shenhong Wu
Journal:  JAMA       Date:  2011-02-02       Impact factor: 56.272

Review 3.  Optimal schedule of paclitaxel: weekly is better.

Authors:  Ana M Gonzalez-Angulo; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2008-04-01       Impact factor: 44.544

4.  Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

Authors:  Harold J Burstein
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

5.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

Authors:  Nicholas J Robert; Véronique Diéras; John Glaspy; Adam M Brufsky; Igor Bondarenko; Oleg N Lipatov; Edith A Perez; Denise A Yardley; Stephen Y T Chan; Xian Zhou; See-Chun Phan; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

6.  Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

Authors:  Marco Colleoni; Anita Giobbie-Hurder; Meredith M Regan; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; István Láng; Ian Smith; Jacquie Chirgwin; Tadeusz Pienkowski; Andrew Wardley; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

7.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

8.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245
  8 in total
  9 in total

Review 1.  Molecular-targeted nanotherapies in cancer: enabling treatment specificity.

Authors:  Elvin Blanco; Angela Hsiao; Guillermo U Ruiz-Esparza; Matthew G Landry; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Oncol       Date:  2011-10-25       Impact factor: 6.603

Review 2.  Unravelling the complexity of metastasis - molecular understanding and targeted therapies.

Authors:  Nilay Sethi; Yibin Kang
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

3.  Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.

Authors:  David I Bellovin; Bikul Das; Dean W Felsher
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 4.  Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.

Authors:  P Bachireddy; K Rakhra; D W Felsher
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

5.  Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.

Authors:  Sarah E Bohndiek; Mikko I Kettunen; De-en Hu; Kevin M Brindle
Journal:  Cancer Res       Date:  2012-01-05       Impact factor: 12.701

6.  Evolutionary dynamics of cancer in response to targeted combination therapy.

Authors:  Ivana Bozic; Johannes G Reiter; Benjamin Allen; Tibor Antal; Krishnendu Chatterjee; Preya Shah; Yo Sup Moon; Amin Yaqubie; Nicole Kelly; Dung T Le; Evan J Lipson; Paul B Chapman; Luis A Diaz; Bert Vogelstein; Martin A Nowak
Journal:  Elife       Date:  2013-06-25       Impact factor: 8.140

7.  Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.

Authors:  Andrea Weiss; Xianting Ding; Judy R van Beijnum; Ieong Wong; Tse J Wong; Robert H Berndsen; Olivier Dormond; Marchien Dallinga; Li Shen; Reinier O Schlingemann; Roberto Pili; Chih-Ming Ho; Paul J Dyson; Hubert van den Bergh; Arjan W Griffioen; Patrycja Nowak-Sliwinska
Journal:  Angiogenesis       Date:  2015-04-01       Impact factor: 9.596

8.  A streamlined search technology for identification of synergistic drug combinations.

Authors:  Andrea Weiss; Robert H Berndsen; Xianting Ding; Chih-Ming Ho; Paul J Dyson; Hubert van den Bergh; Arjan W Griffioen; Patrycja Nowak-Sliwinska
Journal:  Sci Rep       Date:  2015-09-29       Impact factor: 4.379

9.  Rational design of non-resistant targeted cancer therapies.

Authors:  Francisco Martínez-Jiménez; John P Overington; Bissan Al-Lazikani; Marc A Marti-Renom
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.